Webcast Scheduled for Thursday, April 3 at 8:30 a.m. Eastern Time

Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that it filed its annual report on Form 10-K for the year ended December 31, 2013. The Company will host a conference call on Thursday, April 3, 2014, at 8:30 a.m. EDT during which it will provide a corporate update.

Interested parties may access the call live by dialing (888) 264-3177 and using conference ID 87114671. This event is also being streamed via webcast. The webcast is available at http://engage.vevent.com/rt/act~advancedcelltechnology040314 . A replay of the call will also be available via the same link.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a Marlborough, Mass.-based biotechnology company focused on the development and commercialization of human embryonic stem cell (hESC) and adult stem cell technology. The company’s most advanced products are in clinical trials for the treatment of dry age-related macular degeneration and Stargardt’s macular degeneration. ACT’s preclinical programs involve cell therapies for the treatment of other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders. The company’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs. For more information, http://www.advancedcell.com or connect with the Company on Facebook, Twitter, LinkedIn, Google+, and YouTube.

Investors:CEOcast, Inc.Bob Woods, 212-732-4300orPress:Russo PartnersDavid Schull, 858-717-2310